{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    10,
    23,
    27,
    29,
    41,
    50
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Treatment beyond progression criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.6",
        "sectionTitle": "Treatment beyond progression",
        "description": "Reference to protocol-defined conditions for treating subjects beyond disease progression"
      },
      {
        "id": "ref_2",
        "name": "Safety Monitoring Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6",
        "sectionTitle": "Adverse Events",
        "description": "Reference to the full description of ongoing safety monitoring"
      },
      {
        "id": "ref_3",
        "name": "DMC Oversight Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1",
        "sectionTitle": "Data Monitoring Committee",
        "description": "Reference to the Data Monitoring Committee oversight and safety considerations"
      },
      {
        "id": "ref_4",
        "name": "Correlative Studies Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.6.1",
        "sectionTitle": "Correlative Studies",
        "description": "Reference to tumor tissue requirements for correlative studies"
      },
      {
        "id": "ref_5",
        "name": "Alpha Update Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.4.2.1",
        "sectionTitle": "Analysis of OS",
        "description": "Reference to the update of overall alpha in the statistical analysis section"
      },
      {
        "id": "ref_6",
        "name": "RECIST 1.1 Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 1",
        "sectionTitle": "RECIST 1.1",
        "description": "Reference to tumor measurement criteria and progression definitions"
      },
      {
        "id": "ref_7",
        "name": "Child-Pugh Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "CHILD-PUGH SCORE",
        "description": "Reference to cirrhotic status classification"
      },
      {
        "id": "ref_8",
        "name": "ECOG Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 3",
        "sectionTitle": "ECOG PERFORMANCE STATUS",
        "description": "Reference to performance status scale"
      },
      {
        "id": "ref_9",
        "name": "Sorafenib Treatment Beyond Progression",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.5.3.4",
        "sectionTitle": "Provisions for treatment beyond progression",
        "description": "Reference to specific sorafenib dosing provisions after progression"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Subjects may be treated beyond disease progression under protocol-defined conditions. See Section 3.1.6",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Study Design",
        "pageNumber": 4
      },
      {
        "id": "annot_2",
        "text": "Fine needle aspiration (FNA) and bone metastases samples are not acceptable for submission",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Study Population / Inclusion Criteria",
        "pageNumber": 30
      },
      {
        "id": "annot_3",
        "text": "Refer to the sorafenib SmPC for additional details",
        "annotationType": "Reference",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Sorafenib Dose and Schedule",
        "pageNumber": 51
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "04",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-01-15",
        "description": "Incorporates Amendment 18 and Administrative Letter 04; updates for nivolumab guidance and tumor inflammation exploratory objective",
        "amendmentNumber": "Amendment 18"
      },
      {
        "id": "ver_2",
        "versionNumber": "03",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-08-15",
        "description": "Incorporates Amendment 16 and Administrative Letters 02 and 03; ORR changed to secondary objective",
        "amendmentNumber": "Amendment 16"
      },
      {
        "id": "ver_3",
        "versionNumber": "02",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-08-24",
        "description": "Incorporates Amendment 11; Co-primary endpoint changed from TTP to ORR",
        "amendmentNumber": "Amendment 11"
      },
      {
        "id": "ver_4",
        "versionNumber": "01",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-10-01",
        "description": "Incorporates Amendment 02; Addition of PBMC and MDSC collection",
        "amendmentNumber": "Amendment 02"
      }
    ],
    "summary": {
      "referenceCount": 9,
      "annotationCount": 3,
      "versionCount": 4
    }
  }
}